Dupilumab
2018P002882
Approved small_molecule active
Quick answer
Dupilumab for Allergic Contact Dermatitis is a Approved program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Allergic Contact Dermatitis
- Phase
- Approved
- Modality
- small_molecule
- Status
- active